| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $281.4M | +33.5% |
| SG&A Expense | $62.5M | +99.0% |
| Operating Income | -$343.9M | -42.0% |
| Net Income | -$317.4M | -34.5% |
| EPS (Basic) | -$3.37 | +14.7% |
| EPS (Diluted) | -$3.37 | +14.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $435.4M | +258.0% |
| Current Assets | $659.3M | +409.6% |
| Total Assets | $691.2M | +318.7% |
| Current Liabilities | $42.3M | -17.3% |
| Total Liabilities | $61.4M | -16.8% |
| Stockholders' Equity | $629.8M | +589.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$292.4M | -55.4% |
| Capital Expenditures | $2.4M | +225.9% |
| Investing Cash Flow | -$204.1M | -345.0% |
| Financing Cash Flow | $809.9M | +1390.9% |
| Free Cash Flow | -$294.7M | -56.0% |